mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization in children aged 6 months to 5 years
Aglipay, M.; Maguire, J. L.; Swayze, S.; Tuite, A.; Mamdani, M.; Keown-Stoneman, C.; Birken, C. S.; Kwong, J. C.
Show abstract
ImportanceData on mRNA-1273 (Moderna) vaccine effectiveness in children aged 6 months to 5 years are limited. ObjectiveTo assess mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization among children aged 6 months to 5 years. Design, Setting, and ParticipantsA test-negative study using linked health administrative data in Ontario, Canada. Participants included symptomatic children aged 6 months to 5 years who were tested by RT-PCR. ExposuresmRNA-1273 vaccination. Main Outcomes and MeasuresSymptomatic SARS-CoV-2 infection and COVID-19-related hospitalization. ResultsWe included 3467 test-negative controls and 572 test-positive cases. Receipt of mRNA-1273 was associated with reduced symptomatic SARS-CoV-2 infection (VE=90%; 95%CI: 53, 99%) and COVID-19-related hospitalization (VE=82%; 95%CI: 4, 99%) [≥]7 days after the second dose. Conclusions and RelevanceOur findings suggest mRNA-1273 vaccine effectiveness is initially strong against symptomatic SARS-CoV-2 infection and hospitalization in children aged 6 months to 5 years. Further research is needed to understand long-term effectiveness and the need for booster doses.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Pediatric household transmission of SARS-CoV-2 infection 91%
- Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents: an exploratory EHR-based cohort study from the RECOVER program 91%
- Asymptomatic COVID-19 screening tests to facilitate full-time school attendance: model-based analysis of cost and impact 88%
Similar papers in this journal
- Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study 95%
- Risk factors for severe COVID-19 in hospitalized children in Canada: A national prospective study from March 2020–May 2021 93%
- Time-Varying Effectiveness of Three Covid-19 Vaccines in Puerto Rico 92%
Similar papers in this journal
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 96%
- Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada 95%
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada 94%
Similar papers in this journal
- Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting 95%
- 2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims 94%
- Implementation and Adherence to Regular Asymptomatic Testing in a COVID-19 Vaccine Trial 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.